Psoriatic Arthritis
Conference Coverage
Infliximab biosimilar noninferior to originator in IBD – NOR-SWITCH
CHICAGO – Can use of biosimilars save money for IBD patients and health care systems?
From the Journals
Adalimumab outperforms methotrexate in treating severe pediatric plaque psoriasis
A phase III study provided promising data on the efficacy of adalimumab in children and adolescents with severe plaque psoriasis.
Conference Coverage
Some data support botulinum toxin for psoriasis and rosacea
ORLANDO – Can psoriasis and rosacea symptoms be significantly improved with neuromodulator treatment?
From the Journals
Study underscores antipsoriatic effect of gastric bypass surgery
Psoriasis improvement may be based on postoperative hormonal changes plus weight loss.
News
Renflexis approved as second infliximab biosimilar
Infliximab-abda is approved for all indications as reference product, including Crohn’s diseases in adults and children, ulcerative colitis,...
From the Journals
Risankizumab tops ustekinumab in phase II psoriasis trial
In a phase II study, 77% of patients treated with an investigational agent, risankizumab, achieved least a PASI 90 response at 12 weeks, compared...
Conference Coverage
How to get the most out of methotrexate for psoriasis
WAILEA, HAWAII – Methotrexate is the most cost-effective way to manage extensive psoriasis.
From the Journals
Secukinumab beat etanercept in 52-week psoriasis quality of life analysis
Secukinumab was associated with faster and greater improvements in self-reported quality of life in psoriasis patients, compared with etanercept...
Conference Coverage
What’s old is new in topical psoriasis therapy
WAILEA, HAWAII – Fixed-combination halobetasol/tazarotene lotion proves safe and effective in phase II study.
Conference Coverage
Ixekizumab found superior to ustekinumab in psoriasis at 24 weeks
ORLANDO – At 24 weeks, the IL-17A blocker ixekizumab was superior to the IL-12/IL-23 blocker ustekinumab in moderate to severe plaque psoriasis....
From the Journals
Shingles vaccine deemed effective in people with autoimmune disease
Older adults with an autoimmune disease benefited for about 5 years before the vaccine’s effectiveness began to wane.